CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions		Apr. 03, 2022	Dec. 31, 2021
Assets
Cash and cash equivalents		$ 2,470	$ 1,944
Short-term investments		21,427	29,125
Trade accounts receivable, less allowance for doubtful accounts: 2022—$492; 2021—$492		13,225	11,479
Inventories	[1]	9,979	9,059
Current tax assets		3,117	4,266
Other current assets		4,202	3,820
Total current assets		54,420	59,693
Equity-method investments		15,995	16,472
Long-term investments		4,742	5,054
Property, plant and equipment, less accumulated depreciation: 2022—$15,358; 2021—$15,074		15,109	14,882
Identifiable intangible assets	[2],[3]	29,816	25,146
Goodwill	[4]	50,211	49,208
Noncurrent deferred tax assets and other noncurrent tax assets		5,668	3,341
Other noncurrent assets		7,879	7,679
Total assets		183,841	181,476
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2022—$260; 2021—$1,636		645	2,241
Trade accounts payable		5,506	5,578
Dividends payable		0	2,249
Income taxes payable		3,177	1,266
Accrued compensation and related items		2,249	3,332
Deferred revenues		3,108	3,067
Other current liabilities		24,583	24,939
Total current liabilities		39,268	42,671
Long-term debt		35,656	36,195
Pension benefit obligations		3,261	3,489
Postretirement benefit obligations		233	235
Noncurrent deferred tax liabilities		655	349
Other taxes payable		11,574	11,331
Other noncurrent liabilities		10,508	9,743
Total liabilities		101,155	104,013
Commitments and Contingencies
Common stock		476	473
Additional paid-in capital		90,844	90,591
Treasury stock		(113,931)	(111,361)
Retained earnings		111,193	103,394
Accumulated other comprehensive loss		(6,157)	(5,897)
Total Pfizer Inc. shareholders’ equity		82,424	77,201
Equity attributable to noncontrolling interests		261	262
Total equity		82,685	77,462
Total liabilities and equity		$ 183,841	$ 181,476

[1] The change from December 31, 2021 reflects increases for Paxlovid and Comirnaty, as well as increases for certain products mainly for network strategy and supply recovery, partially offset by decreases due to market demand.

[2] The increase in the gross carrying amounts mainly reflect the impact of the acquisition of Arena. See Note 2A.

[3] The increase is primarily due to the acquisition of Arena, partially offset by amortization expense.

[4] All goodwill is assigned within the Biopharma reportable segment.